Malignant melanoma stage IV – Diagnostics – Overview of Information and Clinical Research

When melanoma reaches stage IV, it means the cancer has traveled beyond its original location to distant parts of the body, such as the lungs, liver, brain, bones, or other organs. Understanding how doctors identify and confirm this advanced stage is crucial for determining the most appropriate treatment approach and giving patients the clearest picture of what lies ahead.

Introduction: Who Should Undergo Diagnostics

Diagnosing stage IV melanoma involves confirming that the cancer has spread from the skin to other organs or distant locations in the body. This stage, also called metastatic melanoma or advanced melanoma, represents the most serious form of the disease. The journey to this diagnosis typically begins much earlier, when someone first notices an abnormal mole or skin change, but stage IV is confirmed when doctors find evidence that the cancer has traveled beyond the original tumor site and nearby lymph nodes to distant organs.^[1]

Anyone who has already been diagnosed with melanoma at an earlier stage should remain vigilant and attend all follow-up appointments. Stage IV melanoma doesn’t happen overnight—it develops when earlier-stage melanoma isn’t caught in time or when the cancer returns after initial treatment. People who should undergo diagnostic testing for possible stage IV melanoma include those who have had melanoma before and notice new symptoms, those with earlier-stage melanoma showing signs that it may have spread, or individuals experiencing unexplained symptoms that could indicate metastatic disease.^[2]

The most common places where melanoma spreads include the lungs, liver, bones, brain, small intestine, and distant areas of the skin or soft tissues. Soft tissues are muscles, nerves, fat, and blood vessels. Sometimes melanoma spreads to lymph nodes that are far away from the original tumor. Because melanoma can spread to multiple organs at once, thorough diagnostic testing is essential to understand the full extent of the disease.^[3]

Symptoms that should prompt someone to seek medical attention include persistent coughs that don’t go away, unexplained weight loss, ongoing fatigue that doesn’t improve with rest, headaches that are new or different from usual patterns, abdominal pain or changes in bowel habits, bone pain, or lumps appearing under the skin. These signs don’t always mean stage IV melanoma, but they warrant investigation, especially in someone with a melanoma history.^[6]

⚠️ Important

Stage IV melanoma is diagnosed only after receiving your melanoma diagnosis and determining that cancer cells have traveled through the blood or lymphatic system to other parts of the body. Disease staging happens after the initial melanoma diagnosis is confirmed, not before. If you notice concerning skin changes but haven’t been diagnosed with melanoma yet, your doctor will first confirm whether you have melanoma before determining its stage.

Diagnostic Methods for Identifying Stage IV Melanoma

The diagnosis of stage IV melanoma begins with a careful process that combines physical examination, imaging studies, and laboratory tests. Doctors use a system called TNM staging, which stands for Tumor, Node, and Metastasis. This system helps describe the cancer in detail by looking at the size of the original tumor, whether lymph nodes contain cancer cells, and whether the cancer has spread to distant parts of the body. In stage IV melanoma, the TNM designation is “Any T, Any N, M1,” meaning the tumor can be any size, lymph nodes may or may not be involved, but there is definite evidence of distant spread.^[2]

Before doctors can diagnose stage IV melanoma, they must first confirm the presence of melanoma itself. This initial diagnosis typically happens through an excision biopsy, where a doctor removes the suspicious area of skin along with a small amount of surrounding tissue. A specialist doctor called a pathologist examines this tissue sample under a microscope to look for melanoma cells. If melanoma is found, the pathologist determines characteristics like how thick the melanoma is and whether the surface appears broken or ulcerated, which helps predict how the cancer might behave.^[2]

Once melanoma is confirmed, additional tests help determine whether it has spread to become stage IV disease. The staging system is based on guidelines from the American Joint Committee on Cancer, which assigns a stage based on multiple factors with the goal that melanomas at the same stage will have similar characteristics, treatment options, and expected outcomes. This standardized approach helps doctors communicate clearly and choose the best treatment plan.^[1]

Imaging tests play a central role in diagnosing stage IV melanoma because they allow doctors to see inside the body without surgery. Computed tomography scans, also called CT scans, use special X-ray equipment and computers to create detailed three-dimensional images of the inside of the body. CT scans are particularly useful for detecting melanoma that has spread to the chest, abdomen, or pelvis. They can reveal tumors in the lungs, liver, or other organs that wouldn’t be visible during a physical exam.^[2]

Another important imaging test is magnetic resonance imaging, or MRI. MRI scans use powerful magnets and radio waves instead of X-rays to create detailed pictures of organs and tissues. MRI is especially valuable for examining the brain and spinal cord, as melanoma sometimes spreads to these areas. When doctors suspect brain metastases, an MRI provides much clearer images than other types of scans and can detect even small tumors.^[2]

Positron emission tomography, known as PET scans, represent another key diagnostic tool. During a PET scan, a small amount of radioactive sugar is injected into the body. Cancer cells, which grow rapidly and use more energy than normal cells, absorb more of this radioactive sugar. The PET scanner then creates images showing where the radioactive material has concentrated, highlighting areas of active cancer. Sometimes doctors combine PET scans with CT scans in a single test called a PET-CT scan, which provides both metabolic and structural information about potential tumors.^[2]

Blood tests don’t directly diagnose stage IV melanoma, but they provide important supporting information. One blood test measures lactate dehydrogenase, often abbreviated as LDH. This enzyme is released by damaged cells throughout the body. When melanoma has spread extensively, especially to the liver or other organs, LDH levels in the blood often rise. Elevated LDH levels can indicate more advanced disease and may affect prognosis. However, high LDH alone doesn’t prove stage IV melanoma—imaging studies must confirm the presence of metastatic tumors.^[10]

Sometimes doctors need tissue samples from suspected metastatic sites to confirm the diagnosis. If imaging shows a suspicious mass in the liver, lung, or another organ, a biopsy may be performed. During a biopsy, a small piece of tissue is removed using a needle or during a minor surgical procedure. The pathologist then examines this tissue under a microscope to determine whether it contains melanoma cells. This confirmation is particularly important when the imaging findings are unclear or when knowing the exact nature of a tumor will change the treatment plan.^[2]

Chest X-rays provide a simpler, less expensive way to check whether melanoma has spread to the lungs. While not as detailed as CT scans, chest X-rays can identify larger tumors or significant changes in the lungs. They’re often used as an initial screening tool, with more detailed imaging ordered if the X-ray shows abnormalities.^[2]

In some cases, doctors perform an examination of lymph nodes that haven’t been previously tested. Even in stage IV disease, understanding which lymph nodes contain cancer helps doctors develop a complete picture of how the disease has spread. This information guides decisions about surgery, radiation therapy, and systemic treatments.^[2]

Diagnostics for Clinical Trial Qualification

Clinical trials offer patients with stage IV melanoma access to new treatments that may work better than currently approved therapies. These research studies are carefully designed to test whether new drugs, drug combinations, or treatment approaches are safe and effective. Because clinical trials are testing unproven treatments, they have strict requirements about who can participate. Understanding the diagnostic tests required for clinical trial enrollment helps patients and their doctors determine whether a trial might be appropriate.^[1]

Before joining a clinical trial, patients typically undergo comprehensive diagnostic testing to confirm their exact stage of melanoma and overall health status. These tests serve multiple purposes: they verify that the patient has stage IV disease as required by the trial, they establish a baseline that researchers can use to measure whether the treatment is working, and they ensure the patient is healthy enough to tolerate the experimental treatment being studied.^[1]

Most clinical trials for stage IV melanoma require recent imaging studies. These might include CT scans of the chest, abdomen, and pelvis, as well as MRI scans of the brain. The trial protocol—the detailed plan describing how the study will be conducted—specifies exactly which imaging tests are needed and how recently they must have been performed. Typically, these scans must be done within four to six weeks before starting the trial treatment. Fresh imaging ensures that doctors have current information about the size, location, and number of metastatic tumors, which is crucial for measuring whether the treatment shrinks these tumors over time.^[7]

Blood tests form another essential component of clinical trial screening. Beyond measuring LDH levels, trials often require a complete blood count to check red blood cells, white blood cells, and platelets. They also measure kidney function through tests that look at creatinine levels and liver function through tests measuring enzymes and proteins produced by the liver. These blood tests help ensure that the patient’s organs are working well enough to process and eliminate the trial drug safely.^[7]

Many clinical trials for melanoma require testing the tumor tissue for specific genetic changes or mutations. The most commonly tested mutation involves the BRAF gene. About half of all melanomas have a BRAF mutation, particularly a change called BRAF V600. Knowing whether a patient’s melanoma has this mutation is crucial because some trials specifically study treatments targeting BRAF-mutated melanomas, while others focus on melanomas without this mutation. The BRAF test is performed on a sample of tumor tissue, either from the original melanoma or from a biopsy of a metastatic site.^[11]

Some trials also test for other genetic markers beyond BRAF. For example, mutations in genes called C-KIT or NRAS might determine eligibility for certain studies. As researchers learn more about the genetic diversity of melanomas, trials increasingly use these genetic tests to match patients with treatments most likely to help them based on their tumor’s molecular characteristics.^[13]

A patient’s performance status represents another key criterion for clinical trial participation. Performance status is a measure of how well someone can carry out daily activities. Doctors typically use standardized scales to rate this, asking questions about whether the patient can care for themselves, work, and engage in physical activities. Most trials accept only patients with good performance status because they’re more likely to tolerate intensive treatments and complete the study protocol.^[7]

The time since initial melanoma diagnosis and any previous treatments received also affect clinical trial eligibility. Some trials specifically seek patients who have never received treatment for their stage IV disease—these are called “first-line” or “treatment-naïve” trials. Other trials are designed for patients whose melanoma has continued growing despite previous treatments—these are “second-line” or “later-line” trials. Diagnostic tests document the patient’s treatment history and confirm whether they meet the trial’s requirements regarding prior therapies.^[1]

Because new treatment approaches are being developed rapidly for stage IV melanoma, patients and their doctors are strongly encouraged to consider clinical trials. The treatments available through trials may offer better outcomes than standard approved therapies. The diagnostic tests required for trial enrollment, while sometimes extensive, provide valuable information that helps both the research team and the patient’s own doctors make the best treatment decisions.^[7]

⚠️ Important

Clinical trials not only provide access to potentially better treatments but also help advance understanding of melanoma, which improves future treatment options for all patients. The rapid development of new drugs and drug combinations means that participating in a clinical trial at the time of initial stage IV diagnosis or when disease progresses may offer significant benefits. Talk with your oncologist about whether a clinical trial might be appropriate for your situation.

Prognosis and Survival Rate

Prognosis

Several factors influence the expected course and outcome for patients with stage IV melanoma. The location where the melanoma has spread plays a significant role in determining prognosis. Patients whose melanoma has spread to the skin, distant lymph nodes, or gastrointestinal tract tend to have better outcomes than those with spread to other locations. Those with isolated lung metastases have intermediate outcomes. Unfortunately, patients whose melanoma has spread to the liver, brain, or bones generally face more challenging prognoses.^[10]

Blood levels of lactate dehydrogenase also affect prognosis. When LDH levels are elevated, indicating more extensive disease or greater tumor burden, the outlook is generally less favorable. Additionally, the number of sites where melanoma has spread matters—disease in a single organ versus multiple organs affects expected outcomes.^[10]

Treatment options for stage IV melanoma have expanded dramatically over the past decade, significantly improving the outlook for many patients. New immunotherapy drugs and targeted therapies have changed what’s possible. Some patients experience long-term disease control, and in certain cases, newer treatments may even cure advanced melanoma. The availability of these newer treatment approaches represents a major shift from earlier years when options were much more limited.^[6]^[8]

Survival Rate

According to the American Cancer Society, the five-year survival rate for stage IV melanoma is approximately thirty-five percent. This means that an estimated thirty-five out of every one hundred people with stage IV melanoma are alive five years after diagnosis. However, the Memorial Sloan Kettering Cancer Center reports that survival rates have increased to around fifty percent due to newer treatment options, particularly immunotherapy drugs called checkpoint inhibitors.^[6]

These survival statistics represent estimates based on data from large groups of patients and don’t predict what will happen for any individual person. Many factors influence an individual’s chances, including age, overall health, response to treatment, and access to the latest therapies. The survival rates also reflect data from patients diagnosed several years ago, before the most recent treatment advances became available. As treatments continue improving, survival rates are expected to rise further.^[6]

Historical data shows that median survival times vary depending on where the melanoma has spread. In one analysis of over fifteen hundred patients, those with metastases to the skin, nodes, or gastrointestinal tract had a median survival of twelve and a half months. Those with isolated lung metastases had a median survival of eight point three months. Patients with liver, brain, or bone metastases had a median survival of four point four months. However, these figures come from before the widespread use of modern immunotherapies and targeted treatments, so current outcomes are likely more favorable.^[10]

The ten-year survival rate for patients with metastatic melanoma has historically been less than ten percent. However, medical professionals emphasize that newer treatments are changing this picture. Some patients treated with modern immunotherapy achieve durable responses lasting many years, and a small percentage may be cured. The landscape of stage IV melanoma treatment and survival has transformed dramatically, giving patients and their families more reason for hope than was possible just a decade ago.^[10]^[8]

#1 Clinical Trials Search in Europe